Ticker brief
ACAD ACADIA PHARMACEUTICALS INC
Consumer, Non-cyclical · Biotechnology
last close
$29.11
1 day
-2.1%
14 days
+3.1%
mkt cap
·
signals 14d
6
authors 14d
4
crowd 14d
+0.61
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-24 · now +0.50 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @DanielMuvdiYT | B | +2.24 | 3 | +0.67 |
| @Quantumup1 | C | · | 1 | +0.40 |
| @OzmosiHealth | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.50 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-24 | @BiopharmIQ | +0.50 | Dense biotech list reports trial, PDUFA, filing and approval developments with market moves. | -1.8% | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.50 | European Commission approved Daybu as the first EU treatment for Rett syndrome symptoms. | -1.8% | tweet ↗ |
| 2026-08-18 | @DanielMuvdiYT | +0.50 | Reports ACAD gained 4% in one day and promotes a portfolio recap video. | -3.5% | tweet ↗ |
| 2026-08-17 | @DanielMuvdiYT | +0.70 | A new ACAD position is entering the portfolio. — Explicitly announces a new ACAD portfolio position. | +0.3% | tweet ↗ |
| 2026-08-17 | @DanielMuvdiYT | +0.80 | Initiating ACAD near $28 on valuation and operational normalization. — Announces an ACAD entry near $28 with detailed valuation, growth, balance-sheet and target support. | +0.3% | tweet ↗ |
| 2026-08-17 | @Quantumup1 | +0.40 | UBS reiterated Buy and raised ACAD's target to $49 from $45. | +0.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.